Upstream Bio reports Q3 net loss of $33.7 million on higher R&D expenses
Upstream Bio Inc. reported a net loss of $33.7 million for the third quarter ended September 30, 2025, compared to a net loss of $16.0 million for the same period in 2024. Research and development expenses were $33.0 million, up from $15.4 million, primarily due to increased clinical and manufacturing expenses for the verekitug programs. General and administrative expenses rose to $5.5 million from $4.1 million, mainly driven by higher personnel-related and professional service fees. As of September 30, 2025, the company held $372.4 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027. Key business developments included positive top-line results from the Phase 2 VIBRANT trial of verekitug in CRSwNP, ongoing enrollment in the VENTURE Phase 2 trial in COPD, and plans to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568984-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.